Browsing Tag
respiratory syncytial virus
7 posts
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
November 7, 2024
EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for ABRYSVO, its bivalent respiratory syncytial…
August 28, 2023
FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV
The US Food and Drug Administration (FDA) has granted approval to Pfizer Inc.’s ABRYSVO, a bivalent Respiratory Syncytial…
August 23, 2023
Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status
Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation…
March 27, 2022
Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate
Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from…
March 5, 2022
Thermo Fisher Scientific to acquire Mesa Biotech for $500m to expand point-of-care diagnostics
Thermo Fisher Scientific, a global leader in laboratory and diagnostics solutions, has finalized an agreement to acquire Mesa…
January 20, 2021
Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates
US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines.…
June 22, 2020